Congestive heart failure refers to a chronic progressive condition that affects the pumping capability of the heart muscles. Berliner & Bauersachs (2017) argue that congestive heart failure is increasing worldwide, particularly among aging populations. Therefore, there is a need to strengthen acute care for patients suffering from cardiovascular illnesses. Additionally, the increased hospitalizations associated with cardiac decompensation exacerbate the economic burden among those living with poverty and vulnerable members of society. There are increased innovations to ensure the effectiveness of modern drugs for the treatment of heart failure (HF) and providing patients with therapeutic recommendations to ameliorate the morbidity and mortality of HF patients (Berliner & Bauersachs, 2017). Therefore, the article under review provides a comprehensive overview of the best pharmacological practices that are applicable in managing HF patients per the 2016 guidelines of the European Society of Cardiology.
Patients with HF (HFrEF) should receive neurohormonal inhibition that works based on the principle of angiotensin-converting enzyme inhibitors. The inhibitor work best in combination with mineralocorticoid receptor antagonists and beta-blockers. Beta-blockers are effective in ameliorating the peripheral perfusion to ensure the increased heart rate and myocardial contractility. The use of angiotensin-II to treat the complication regulates the rate at which aldosterone is synthesized by plasma potassium. Furthermore, Berliner & Bauersachs (2017) assert the use of diuretics in treating HF to improve the symptoms of the disease such as dyspnea and edema. The Angiotensin Receptor-Neprilysin Inhibitor (ARNI) facilitates the degradation of natriuretic peptides while the inhabitation of neprilysin curtails neurohumoral activation that could increase vasoconstriction, cardiac remodeling, and sodium retention (Berliner & Bauersachs, 2017). Therefore, the overall goal of treating patients with HFpEF is to improve the symptoms associated with the condition and the individuals’ wellbeing.
Delegate your assignment to our experts and they will do the rest.
In conclusion, the article is worth reading not only by medics but by everyone. Acquiring the information communicated in the article can help HF patients and their relatives to be aware of the increasing prevalence of the disease, its therapy, and prevention measures. The information on the appropriate drug therapy is vital for medical professionals to ensure that they prescribe doses that conform to the current guidelines for HF patients.
Reference
Berliner, D. & Bauersachs, J. (Apr 13, 2017). Current Drug Therapy in Chronic Heart Failure - the New Guidelines of the European Society of Cardiology (ESC). Korean Circ J. , 47(5):543-554. The Korean Society of Cardiology. Retrieved February 14, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614938/pdf/kcj-47-543.pdf
